Margherita Calcagnino has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • Perry Mark Elliott

    Institute of Cardiovascular Science and British Heart Foundation Centre of Research Excellence, University College London, United Kingdom; Department of Inherited Cardiovascular Diseases, Barts Heart Centre, St Bartholomew’s Hospital, London, United Kingdom (P.M.E.).

    5 shared publications
  • Constantinos O'MAhony

    Barts Health NHS Trust, London, United Kingdom

    4 shared publications
  • Colomba Falcone

    Interdepartmental Center for Research in Molecular Medicine (CIRMC), University of Pavia, Viale Taramelli 24, I-27100, Pavia, Italy

    3 shared publications
  • Enzo Emanuele

    E Science, I-27038 Robbio, PV, Italy

    3 shared publications
  • Montserrat Cardona

    Inherited Cardiac Diseases Unit , The Heart Hospital/University College London , 16-18 Westmoreland Street, London W1G 8PH , UK

    3 shared publications
  • Stefano Carugo

    Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy

    3 shared publications

Latest Publications

  • Open Access

    What Should a Clinical Cardiologist Know About Cardiogenetics?

    by Andrea Faggiano, Margherita Maria Calcagnino, Marco Merlo, Matteo Dal Ferro, Francesco Moda, Marta Sanfilippo, Laura Garau, Chiara Giordano, Alessia Paldino, Marta Gigli, et al.

    Inherited cardiovascular diseases are becoming increasingly prominent in clinical practice, significantly impacting diagnosis, risk assessment, and family screening strategies. Progress in genetic testing has broadened access to cardiogenetic evaluations, while also presenting new challenges in interpreting variants and incorporating findings into clinical care. This narrative review explores 20 essential questions that clinical cardiologists may face when dealing with suspected or confirmed inherited cardiac conditions. Organized as a practical, question‐driven guide, it outlines when to consider a genetic cause, how to choose and interpret genetic tests, and how to manage patients regardless of their genetic test results. The review emphasizes variant classification based on American College of Medical Genetics and Genomics criteria, the importance of clinical context in interpreting uncertain results, and the principles behind family cascade screening. Particular attention is given to the management of relatives who carry a genetic variant but show no symptoms, and to the current limitations of genetic testing technologies (eg, performance). Ethical considerations, including the appropriate timing of testing in children minors, are also discussed. By connecting genetic insights with clinical cardiology, this review aims to support practical, informed decision making and promote effective collaboration with cardiogenetic specialists.


  • Open Access

    How to Enhance Diagnosis in Fabry Disease: The Power of Information

    by Maria Chiara Meucci, Rosa Lillo, Margherita Calcagnino, Giampaolo Tocci, Eustachio Agricola, Federico Biondi, Claudio Di Brango, Vincenzo Guido, Valentina Parisi, Francesca Giordana, et al.

    Background: Cardiac involvement is common in Fabry disease (FD) and typically manifests with left ventricular hypertrophy (LVH). Patients with FD are frequently misdiagnosed, and this is mainly related to the lack of disease awareness among clinicians. The aim of this study was to determine whether providing a targeted educational intervention on FD may enhance FD diagnosis. Methods. This research was designed as a single-arm before-and-after intervention study and evaluated the impact of providing a specific training on FD to cardiologists from different Italian centers, without experience in rare diseases. In the 12-month period after the educational intervention, the rate of FD screening and diagnosis was assessed and compared with those conducted in the two years preceding the study initiation. Results: Fifteen cardiologists participated to this study, receiving a theoretical and practical training on FD. In the two previous two years, they conducted 12 FD screening (6/year), and they did not detect any cases of FD. After the training, they performed 45 FD screenings, with an eight-fold rise in the annual screening rate. The screened population (age: 61 ± 11 years, men: 82%) was mainly composed of patients with unexplained LVH (n = 43). There were four new FD diagnoses and, among of them, three had a late-onset GLA variant. After the cascade genetic screening, 11 affected relatives and 8 heterozygous carriers were also detected. Conclusions: A targeted educational intervention for cardiologists allowed the identification of four new families with FD. Enhancing FD awareness is helpful to reduce the diagnostic and therapeutic delay.

  • Open Access

    P87 GENETIC CARDIOMYOPATHIES: THE FIRST YEAR OF THE FONDAZIONE IRCCS CÀ GRANDA OSPEDALE MAGGIORE POLICLINICO OF MILAN DEDICATED CLINICAL SERVICE

    by A Faggiano, M Calcagnino, S Paganini, M Ruscica, S Carugo

    Cardiac genetic counselling and testing for inherited cardiomyopathies have become essential aspects of cardiovascular care. A genetic diagnosis in a family can offer an invaluable tool for cascade genetic testing of at–risk relatives. A careful clinical and individualized approach to genetic cardiomyopathies is now needed to guarantee the best care possible. We report the results of our first–year genetic cardiomyopathies single–centre experience. From September 2021, 69 genetic tests have been carried out at Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan by the staff of a new specific clinical service dedicated to genetic cardiomyopathies. The present study collects the data of 69 patients who underwent genetic testing and clinical follow up at our centre in suspicion of underlying genetic etiology of disease. Next generation sequencing was adopted to conduct genetic testing either by a customized panel of 54 specific genes for cardiomyopathies or by a clinical exome (180 genes). Time required for reporting and patient communication were 8 and 12 weeks, respectively. Female sex was 36%, mean age was of 53.2 ± 21.3 years. The main indications for genetic testing were dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). Figure 1. 41% of DCM and 50% of HCM patients tested positive for a pathogenic or likely pathogenetic mutation. Cascade genetic tests conducted on at–risk relatives were 21 (30%). Among these subjects, 38% resulted positive at genetic screening and 57% were in turn positive at phenotypic screening. The genes hit by pathogenic or likely pathogenetic mutations are illustrated in Figure 2.

  • Open Access

    ADIPOSITY AND VASCULAR AGEING: WHICH PARAMETER BETTER CORRELATES?

    by Alessandro Guareschi, Marco Vicenzi, Margherita Calcagnino, Stefano Carugo, Angelo Scuteri

    Objective: The increase in stiffness of large arteries is one of the mechanisms that could play a role in the association between obesity and increased risk of cardiovascular (CV) events. Carotid-femoral pulse wave velocity (cfPWV) represents a validated measure of large arteries stiffness and a good proxy of arterial ageing. We aimed at evaluating which body composition parameters better correlated with cfPWV and whether this correlation differed between men and women. Design and method: cfPWV was measured in all subjects; body composition was evaluated by bioimpedance analysis and waist circumference (W). Furthermore, each subject was characterized by sex, age, height, weight, body mass index (BMI), brachial blood pressure (BP) and heart rate. A linear correlation was used to define the relationship between cfPWV and parameters. Univariate and multivariate analysis were performed in male and female subgroup separately to select the main determinants of arterial stiffness, considering the following parameters: age, mean BP (mBP), BMI, W, fat mass (FM) and skeletal muscle mass (SMM). We enrolled 69 subjects (37 men, 32 women) with average age 34.5 years (min 19-max 76). Results: cfPWV was significantly correlated with age (r = 0.65, p < .0001), and mBP (r = 0.38, p < .01). Among the body composition parameters, W, BMI and FM percentage were significantly correlated with cfPWV (respectively: r = 0.48, r = 0.42, r = 0.41; p < .0001). Multivariable regression analysis in men revealed that age and mBP were significant determinants of cfPWV (respectively: b = 0.042, p = 0.002; b = 0.051, p = 0.004). Conversely, multivariate analysis in women showed that age, FM and SMM are retained as main determinants of increased cfPWV (respectively: b = 0.079; p < 0.0001; b = 0.217, p = 0.012; b = 0.125, p = 0.011). Conclusions: Irrespectively of gender, age is the main determinant of arterial stiffness. Our results demonstrated that the relationship between adiposity and arterial stiffness is verified only in female subjects. This suggests that this relationship is influenced by complex and not fully known mechanisms. Moreover, technical factors (algorithm and indirect methods to assess body composition) contribute to uncertainty regarding which parameter exploring adiposity is more accurate in stratifying CV risk. The present study recalls attention on possible gender-specific determinants of arterial ageing.

  • Open Access

    Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy

    by Gabrielle Norrish, Tao Ding, Ella Field, Elena Cervi, Lidia Ziółkowska, Iacopo Olivotto, Diala Khraiche, Giuseppe Limongelli, Aris Anastasakis, Robert Weintraub, et al.

    Background: Maximal left ventricular wall thickness (MLVWT) is a risk factor for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). In adults, the severity of left ventricular hypertrophy has a nonlinear relationship with SCD, but it is not known whether the same complex relationship is seen in childhood. The aim of this study was to describe the relationship between left ventricular hypertrophy and SCD risk in a large international pediatric HCM cohort. Methods: The study cohort comprised 1075 children (mean age, 10.2 years [±4.4]) diagnosed with HCM (1–16 years) from the International Paediatric Hypertrophic Cardiomyopathy Consortium. Anonymized, noninvasive clinical data were collected from baseline evaluation and follow-up, and 5-year estimated SCD risk was calculated (HCM Risk-Kids). Results: MLVWT Z score was Z scores were associated with heart failure symptoms, unexplained syncope, left ventricular outflow tract obstruction, left atrial dilatation, and nonsustained ventricular tachycardia. One hundred twenty-two patients (71.3%) with MLVWT Z score ≥20 had coexisting risk factors for SCD. Over a median follow-up of 4.9 years (interquartile range, 2.3–9.3), 115 (10.7%) had an SCD event. Freedom from SCD event at 5 years for those with MLVWT Z scores Z score, peaking at Z score +23. The presence of coexisting risk factors had a summative effect on risk. Conclusions: In children with HCM, an inverted U-shaped relationship exists between left ventricular hypertrophy and estimated SCD risk. The presence of additional risk factors has a summative effect on risk. While MLVWT is important for risk stratification, it should not be used either as a binary variable or in isolation to guide implantable cardioverter defibrillator implantation decisions in children with HCM.


  • Open Access

    Outcomes and management of arrhythmogenic right ventricular cardiomyopathy in pregnancy: a case report

    by Marco Schiavone, Margherita Calcagnino, Andrea Mazzanti, Carla Bonanomi

    Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease with an estimated prevalence of up to 1:5000 in the general population. Few cases of ARVC during pregnancy are described in literature. Case summary: A 32-year-old primigravida was referred to our clinic during the 32nd gestational week. Arrhythmogenic right ventricular cardiomyopathy diagnosis with biventricular involvement was made according to Task Force criteria. Beta-blocker therapy was started and an elective caesarean section was planned, during the 37th gestational week; no complications occurred. Thirteen months after delivery, the patient was readmitted in our hospital due to an episode of pre-syncope and after team discussion, an implantable cardioverter-defibrillator (ICD) was implanted. Discussion: This case suggests that the absence of signs and symptoms of heart failure (HF) at a first evaluation plays a major role to predict maternal and foetal outcome in ARVC. Our experience is consistent with the evidence that indicates a favourable outcome in asymptomatic patients treated with optimal medical therapy during pregnancy. In our case, despite no major HF or arrhythmic complications during pregnancy, delivery, and puerperium, we observed an arrhythmic disease progression more likely independent from pregnancy, leading to ICD implantation.


  • Sistema di assistenza ventricolare CircuLite Synergy: un nuovo approccio all’insufficienza cardiaca terminale

    by Alessandro Barbone, Daniela Pini, Diego Ornaghi, Maria Maddalena Visigalli, Laura Ardino, Renato Bragato, Mirko Curzi, Sara Anna Cioccarelli, Lara Di Diodoro, Alessio Basciu, et al.

    Razionale. Il CircuLite Synergy è un innovativo sistema di assistenza ventricolare, che può essere impiantato per via minitoracotomica senza circolazione extracorporea. Ciò potrebbe permettere di allargare le indicazioni di questa terapia a pazienti che non sarebbero altrimenti considerati per l’impianto di un sistema di assistenza ventricolare a causa del rischio chirurgico. Il CircuLite Synergy è stato oggetto di un trial clinico per ottenere il marchio CE; durante il trial ha subito delle modifiche tecniche per ottimizzarne il funzionamento e ridurre l’incidenza di complicanze. Materiali e metodi. Dal giugno 2007 al dicembre 2012 sono stati impiantati 63 pazienti con 4 diverse versioni del sistema. Di questi, 12 avevano un’età ≥70 anni. Il sistema è costituito da una cannula di drenaggio posizionata a livello dell’atrio sinistro, da una micropompa alloggiata in una tasca sottocutanea (tipo pacemaker) in regione sottoclaveare destra e da una protesi in PTFE per la reimmissione del sangue nell’arteria succlavia omolaterale. In questo lavoro analizziamo e riportiamo i dati di una valutazione intermedia al 30 aprile 2013 dello studio che ha portato al marchio CE per il dispositivo. Risultati. La durata media del supporto nel periodo di studio è stata di 230 giorni (range 23-1387). Lo studio ha documentato un miglioramento emodinamico immediato, ma anche un miglioramento della capacità funzionale (con un incremento della distanza percorsa al test del cammino di 6 min da 299 ± 144 a 420 ± 119 m dopo 3 mesi) e della qualità di vita (con una riduzione del punteggio al Minnesota Living with Heart Failure Questionnaire da 69.5 ± 20.4 a 42.2 ± 24.3 dopo 6 mesi). Nei pazienti di età ≥70 anni il sistema si è dimostrato ugualmente efficace e ben tollerato, sebbene il numero di eventi avversi, in particolare il sanguinamento, sia risultato significativamente superiore. Conclusioni. Nel trial clinico per ottenere il marchio CE il sistema Synergy si è dimostrato efficace nel controllare i sintomi e nel migliorare la qualità di vita. In particolare, con l’ultima versione del sistema, sviluppata per superare i limiti delle versioni precedenti, l’incidenza di eventi avversi si è mostrata particolarmente bassa e in linea con quanto riportato in letteratura per altri sistemi di assistenza. In un’analisi per sottogruppi, il sistema si è dimostrato efficace e ben tollerato anche nei pazienti di età ≥70 anni, una popolazione particolarmente fragile in cui però la prevalenza di insufficienza cardiaca è assai elevata.


  • Open Access

    Primary Headache and Silent Myocardial Ischemia in Patients with Coronary Artery Disease

    by Colomba Falcone, Sara Bozzini, Carmine Gazzaruso, Margherita Calcagnino, Natascia Ghiotto, Rossana Falcone, Adriana Coppola, Andrea Giustina, Gabriele Pelissero

    Objective: The mechanisms by which migraine is linked to ischemic vascular disease remain uncertain and are likely to be complex. The aim of this study was to investigate the correlation between silent myocardial ischemia (SMI) and a history of documented primary headache in a large population of patients with exercise-induced myocardial ischemia. Methods: The study involved 1,427 consecutive patients (918 symptomatic and 509 asymptomatic patients) with exercise-induced myocardial ischemia and documented coronary artery disease (CAD). Results: Patients with anginal symptoms during exercise-induced myocardial ischemia had a significantly higher prevalence of primary headache than those without (41 vs. 30%, p < 0.001). Patients with angina pectoris in daily life also had greater prevalence of primary headache than those without anginal symptoms (37 vs. 20%; p < 0.0001). Symptomatic patients during percutaneous transluminal coronary angiography or myocardial infarction had a greater prevalence of primary headache than asymptomatic patients (p < 0.001 and p = 0.005, respectively). Conclusions: Our data suggest that a history of headache in CAD population is correlated to a high probability of anginal symptoms and a decreased probability of SMI. The anamnestic absence of headache requires a close monitoring for patients with risk factors for CAD, because this population seems to have a lower susceptibility to pain and the risk of developing SMI might be increased.


  • Rage Gene Polymorphism in Heart Failure Patients with and without Angiographic Evidence of Significant Coronary Atherosclerosis

    by C. Falcone, S. Bozzini, B. Matrone, A. Colonna, R. Falcone, M. Calcagnino, G. Pelissero

    Heart failure (HF) is a multifactorial disorder in which clinical, environmental and genetic components take part. For this reason it is possible that common gene variants could affect development, progression and response to pharmacological therapy. In recent years the role of AGEs in the pathogenesis of cardiovascular diseases has become recognized but little is known about the role of the AGE-RAGE system in heart failure. The aim of the present study was to identify possible relationship between -374 T/A RAGE gene polymorphism with heart failure. The population in this study consists of 386 subjects with HF, selected according to the presence of depressed Left Ventricular Ejection Fraction (LVEF) <45%, and 639 patients with CAD documented at coronary angiography. Within the population with HF there are 228 patients with disease secondary to not ischemic cause and 158 with post-ischemic condition. The sample of AA genotype was significantly lower in patients with post-ischemic HF in respect to HF secondary to non-ischemic causes (p<0.001). A significant difference between the two groups was also observed regarding the allele frequency. In addition, differences in the allelic and the genotypic frequencies of homozygous genotypes were found between the HF patients free from evidence of coronary significant lesions and patients with at least one hemodynamically significant coronary lesion, both HF and CAD. In patients with at least one vessel compromised the presence of A allele and the homozygous AA genotype were significantly lower than in patients with lesion-free coronary. In conclusion, our research reveals that the -374 T/A polymorphism is related to the genesis of atherosclerotic coronary artery disease but not to its evolution. The protective role of AA genotype in respect to atheromatous disease is therefore confirmed also in the HF population with non-ischemic origin.


  • Open Access

    Usefulness of semi-quantification of ischemic myocardium after adenosine stress magnetic resonance

    by Lorenzo Monti, Marco Tramarin, Margherita Calcagnino, Veronica Lisignoli, Barbara Nardi, Luca Balzarini